DDInter802 DDInter1376
Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as _Galanthus nivalis_. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade.[A182993,A201968] Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Galantamine {u} (Compound) resembles {v} (Compound) Dihydrocodeine
Galantamine {u} (Compound) resembles {v} (Compound) Codeine
Galantamine {u} (Compound) treats {v} (Disease) Alzheimer's disease
Galantamine {u} (Compound) binds {v} (Gene) CHRND
Galantamine {u} (Compound) upregulates {v} (Gene) HERC6
Galantamine {u} (Compound) downregulates {v} (Gene) MBOAT7
Galantamine {u} (Compound) causes {v} (Side Effect) Hypotension
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hyoscyamine
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyclizine
Galantamine {u} may lead to a major life threatening interaction when taken with {v} Bupropion
Galantamine (Compound) resembles Dihydrocodeine (Compound)
Galantamine (Compound) resembles Codeine (Compound)
Galantamine (Compound) treats Alzheimer's disease (Disease)
Galantamine (Compound) binds CHRND (Gene)
Galantamine (Compound) upregulates HERC6 (Gene)
Galantamine (Compound) downregulates MBOAT7 (Gene)
Galantamine (Compound) causes Hypotension (Side Effect)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Galantamine may lead to a major life threatening interaction when taken with Bupropion